Home
HelpTest ID C2NAD PrecivityAD, Plasma
Ordering Guidance
This blood test is intended for use in patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation for Alzheimer disease or other forms of cognitive decline.
Shipping Instructions
1. Specimen should be shipped frozen on dry ice
2. Place labeled aliquot tube inside a larger tube or vial for transport.
Specimen Required
Supplies: Screw cap micro tube, 2 mL, PCR Performance Tested, Low protein-binding (T983)
Collection Container/Tube: 10 mL Purple top (K EDTA)
Submission Container/Tube: 2-mL screw cap micro tubes
Specimen Volume: 1.5 mL
Collection Instructions:
1. Centrifuge within two hours of collection.
2. Aliquot plasma into a 2 mL micro tube.
3. Freeze plasma (no longer than 2 hours after collection) at -20° C or below.
Useful For
Assisting in the evaluation of adult patients, aged 55 years and older, with signs or symptoms of mild cognitive impairment or dementia who are being assessed for Alzheimer disease and other causes of cognitive decline
This is not intended for patients younger than 55 years, or for use as a screening test in patients without signs or symptoms of cognitive impairment, or for serial testing for assessment of longitudinal changes.
Method Name
Immunoprecipitation/Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
PrecivityADSpecimen Type
PlasmaSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma | Frozen | ||
Reference Values
Amyloid Probability Score (APS): 0-100
Low (0-35): Consistent with absence of amyloid plaques
Intermediate (36-57)
High (58- 100): Consistent with presence of amyloid plaques
Abeta42/40 Ratio
≥0.095: Consistent with absence of amyloid plaques
ApoE Proteotype
E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, E4/E4
-E3 is the most common allele.
-E4 allele is associated with increased risk of amyloid plaques.
-E2 allele is associated with lower risk of amyloid plaques.
Day(s) Performed
Monday through Friday
Report Available
10 days post sample receipt from MCL.Performing Laboratory
C2N Diagnostics LLCTest Classification
C2N Diagnostics has developed and determined the analytical and clinical validity performance characteristics of this Laboratory Developed Test (LDT). This assay has been validated pursuant to CLIA regulations and is used for clinical purposes. This assay has not been cleared or approved by the FDA.CPT Code Information
0412U
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| C2NAD | PrecivityAD | Not Provided |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| ND2B | Amyloid Probability Score (APS) | Not Provided |
| ND2BF | APS Result | Not Provided |
| ND2C | Interpretation | Not Provided |
| ND2D | APS Reference Interval | Not Provided |
| ND2E | Patient Age | Not Provided |
| ND2F | Abeta42/40 Ratio | Not Provided |
| ND2G | Abeta42/40 Ratio Reference Interval | Not Provided |
| ND2H | Abeta42/40 Ratio Description | Not Provided |
| ND2I | ApoE Proteotype | Not Provided |
| ND2J | ApoE Proteotype Reference Interval | Not Provided |
| ND2K | Test Description | Not Provided |
| ND2L | Limitations of Test Result | Not Provided |
| ND2M | Methods and Assay Category | Not Provided |
| ND2N | References | Not Provided |
| ND2O | Report Comment | Not Provided |
| ND2P | Performing Site | Not Provided |
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.